ZENOTECH LABORATORIES LTD.

Zenotech Laboratories Ltd has announced the closure of its trading window for dealing in the company's shares. This closure will be effective from Wednesday, July 01, 2026, and will remain in effect for 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated separately. This measure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading, aimed at preventing potential misuse of unpublished price-sensitive information.

Zenotech Laboratories Ltd. announced its audited standalone financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved these results, and an unmodified auditor's opinion was declared. For the fourth quarter of FY26, the company reported a total income of ₹1,047.71 lakhs and a net loss of ₹315.08 lakhs, with basic earnings per share (EPS) of (₹0.52). For the full financial year 2026, Zenotech recorded a total income of ₹4,592.26 lakhs and a net loss of ₹107.21 lakhs, resulting in a basic EPS of (₹0.18). Revenue from operations for Q4 FY26 was ₹886.50 lakhs, while for the full year FY26, it was ₹3,956.20 lakhs.

Zenotech Laboratories Ltd. announced its audited standalone financial results for the quarter and financial year ended March 31, 2026. For Q4 FY26, the company reported a net loss of ₹315.08 lakhs, with revenue from operations at ₹886.50 lakhs. Basic EPS for the quarter was (₹0.52). For the full financial year FY26, the company posted a net loss of ₹107.21 lakhs, on revenue from operations of ₹3,956.20 lakhs. The basic EPS for FY26 was (₹0.18). The Board of Directors approved these results on April 29, 2026.

Zenotech Laboratories Ltd has scheduled a Board of Directors meeting on April 29, 2026, to consider and approve the Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026. The trading window has been closed from April 01, 2026, and will remain closed until May 01, 2026, following the declaration of the financial results.

Zenotech Laboratories Ltd responded to an inquiry from the stock exchange regarding a significant recent movement in its share price. The company confirmed its adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30. Zenotech explicitly stated that it has not withheld any material information or impending announcements that, in its opinion, could be responsible for the recent price behavior of its shares. This clarification was issued on April 10, 2026, in response to an email from the exchange, reiterating the company's commitment to transparency and regulatory compliance.

Zenotech Laboratories Ltd, as per its Code of Conduct for Prohibition of Insider Trading, has announced the closure of the trading window for dealing in the company's shares. The closure will start from April 01, 2026, and will remain in effect until 48 hours after the declaration of the Audited Financial Results for the financial year ending March 31, 2026. The date of the Board Meeting to consider and approve the Audited Financial Results will be communicated in due course.

Zenotech Laboratories Ltd. announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The company's revenue from operations stands at 1,182.60 lakhs for the quarter and 3,069.70 lakhs for the nine months period. The total income for the quarter is 1,327.75 lakhs and 3,544.55 lakhs for the nine months period. The company has approved the appointment of Mr. Nikkhil Venilal Kothhari as an Additional Director (Independent) for a period of 5 years, subject to shareholder's approval. The appointment of Mr. Chintan Jitendra Shah as an Independent Director will end on January 26, 2026.

The Board Meeting of Zenotech Laboratories Ltd held on January 23, 2026 approved the Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2025. The Board also approved the appointment of Mr. Nikkhil Venilal Kothhari as an Additional Director (Independent) for a period of 5 years, subject to shareholder's approval. The meeting also saw the reconstitution of Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee of the Board.

Zenotech Laboratories Ltd has announced that its Board of Directors will meet on January 23, 2026, to consider and approve the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2025. The Trading Window has been closed from January 01, 2026, and will reopen after 48 hours of the declaration of financial results.

Zenotech Laboratories Ltd has announced the closure of its trading window for the quarter and nine months ending December 31, 2025. The closure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading. The trading window will remain closed from January 1, 2026, till 48 hours after the declaration of Unaudited Financial Results for the same period. The date of the Board Meeting to approve the Unaudited Financial Results is yet to be communicated.